Natco Pharma Announcements
Investor Meet
06 Mar, 2026 | 10:26am • Source: BSE
Clarification on volume Movement of Shares
25 Feb, 2026 | 12:03pm • Source: BSE
The Exchange has sought clarification from Natco Pharma Ltd on February 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
25 Feb, 2026 | 11:26am • Source: BSE
Clarification on the News Item
25 Feb, 2026 | 10:06am • Source: BSE
The Exchange has sought clarification from Natco Pharma Ltd on February 24, 2026, with reference to news appeared in https://www.livemint.com dated February 24, 2026 quoting...
24 Feb, 2026 | 04:50pm • Source: BSE
copy of News Paper Publication
21 Feb, 2026 | 11:43am • Source: BSE
Postal Ballot Notice seeking approval for reappointment of Executive Directors of the Company
20 Feb, 2026 | 01:07pm • Source: BSE
Transcript of Q3 FY ''26 Post Results Earnings Conference Call
18 Feb, 2026 | 03:40pm • Source: BSE
copy of News Paper Publication
13 Feb, 2026 | 04:11pm • Source: BSE
Press Release regarding the receipt of Establishment Inspection Report (EIR) for the API Unit of the Company located in Chennai from U.S. Food and Drugs...
13 Feb, 2026 | 09:16am • Source: BSE
Audio recording of earnings conference call Q3 FY25-26
12 Feb, 2026 | 06:07pm • Source: BSE
Board of Directors at their meeting held today declared 3rd Interim Dividend of Rs.1.50 per equity share of Rs.2/- each
12 Feb, 2026 | 04:00pm • Source: BSE
The Board of Directors at their meeting held today approved to incorporate a wholly owned subsidiary in CHILE
12 Feb, 2026 | 03:58pm • Source: BSE
1. Superannuation of Mr. S V V N Appa Rao, Chief Financial Officer w.e.f. closure of business hours on 12th February, 20262. Appointment of...
12 Feb, 2026 | 03:54pm • Source: BSE
Investor Presentation on Q3 earning for FY 2025-26
12 Feb, 2026 | 03:04pm • Source: BSE
Un audited Financial Results for the quarter ending 31st December, 2025
12 Feb, 2026 | 02:49pm • Source: BSE
outcome of the board meeting
12 Feb, 2026 | 02:35pm • Source: BSE
Natco Receives Tentative Approval for Erdafitinib Tables (generic of Balversa) from the United States Food and Drug Administration (U.S.FDA)
03 Feb, 2026 | 02:54pm • Source: BSE
Natco Pharma Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "NATCO receives Tentative Approval for Erdafitinib Tablets (generic of...
03 Feb, 2026 | 01:30pm • Source: NSE
NATCO receives Tentative Approval for Erdafitinib Tablets (generic of Balversa)
03 Feb, 2026 | 01:17pm • Source: BSE